- New Purchases: BMY, 3IP, 3IP, DERM, LTHM, XBIT,
- Added Positions: ICPT, AMRN, LXRX, MYGN, OMED, IMGN, DOVA,
- Reduced Positions: ATRA, VCYT, SITO, ECA, VYGR,
- Sold Out: HROW, AMAG,
For the details of Birchview Capital, LP's stock buys and sells, go to https://www.gurufocus.com/guru/birchview+capital%2C+lp/current-portfolio/portfolio
These are the top 5 holdings of Birchview Capital, LP- Celgene Corp (CELG) - 699,011 shares, 41.48% of the total portfolio.
- Accelerate Diagnostics Inc (AXDX) - 2,183,795 shares, 28.88% of the total portfolio.
- Clementia Pharmaceuticals Inc (CMTA) - 222,000 shares, 3.64% of the total portfolio.
- Neurocrine Biosciences Inc (NBIX) - 55,000 shares, 3.05% of the total portfolio.
- Array BioPharma Inc (ARRY) - 168,000 shares, 2.58% of the total portfolio.
Birchview Capital, LP initiated holding in Bristol-Myers Squibb Company. The purchase prices were between $45.12 and $53.8, with an estimated average price of $49.88. The stock is now traded at around $48.62. The impact to a portfolio due to this purchase was 0.6%. The holding were 20,000 shares as of .
New Purchase: Harrow Health Inc (3IP)Birchview Capital, LP initiated holding in Harrow Health Inc. The purchase prices were between $4.12 and $6.16, with an estimated average price of $5.27. The stock is now traded at around $3.96. The impact to a portfolio due to this purchase was 0.56%. The holding were 180,000 shares as of .
New Purchase: Harrow Health Inc (3IP)Birchview Capital, LP initiated holding in Harrow Health Inc. The purchase prices were between $4.12 and $6.16, with an estimated average price of $5.27. The stock is now traded at around $3.96. The impact to a portfolio due to this purchase was 0.56%. The holding were 180,000 shares as of .
New Purchase: Dermira Inc (DERM)Birchview Capital, LP initiated holding in Dermira Inc. The purchase prices were between $6.19 and $14.13, with an estimated average price of $8.29. The stock is now traded at around $10.23. The impact to a portfolio due to this purchase was 0.17%. The holding were 20,000 shares as of .
New Purchase: Livent Corp (LTHM)Birchview Capital, LP initiated holding in Livent Corp. The purchase prices were between $12.09 and $14.56, with an estimated average price of $13.04. The stock is now traded at around $11.29. The impact to a portfolio due to this purchase was 0.08%. The holding were 10,000 shares as of .
New Purchase: XBiotech Inc (XBIT)Birchview Capital, LP initiated holding in XBiotech Inc. The purchase prices were between $5.05 and $11.62, with an estimated average price of $8.04. The stock is now traded at around $9.20. The impact to a portfolio due to this purchase was 0.07%. The holding were 10,000 shares as of .
Added: Intercept Pharmaceuticals Inc (ICPT)Birchview Capital, LP added to a holding in Intercept Pharmaceuticals Inc by 93.02%. The purchase prices were between $91.83 and $120.68, with an estimated average price of $109.22. The stock is now traded at around $89.92. The impact to a portfolio due to this purchase was 0.28%. The holding were 8,300 shares as of .
Added: Amarin Corp PLC (AMRN)Birchview Capital, LP added to a holding in Amarin Corp PLC by 47.50%. The purchase prices were between $12.61 and $22.33, with an estimated average price of $17.95. The stock is now traded at around $18.14. The impact to a portfolio due to this purchase was 0.25%. The holding were 59,000 shares as of .
Added: Lexicon Pharmaceuticals Inc (LXRX)Birchview Capital, LP added to a holding in Lexicon Pharmaceuticals Inc by 300.00%. The purchase prices were between $4.36 and $7.94, with an estimated average price of $6.1. The stock is now traded at around $6.56. The impact to a portfolio due to this purchase was 0.21%. The holding were 80,000 shares as of .
Added: Myriad Genetics Inc (MYGN)Birchview Capital, LP added to a holding in Myriad Genetics Inc by 100.00%. The purchase prices were between $26.93 and $34.7, with an estimated average price of $30.42. The stock is now traded at around $34.34. The impact to a portfolio due to this purchase was 0.21%. The holding were 20,000 shares as of .
Added: OncoMed Pharmaceuticals Inc (OMED)Birchview Capital, LP added to a holding in OncoMed Pharmaceuticals Inc by 115.90%. The purchase prices were between $0.71 and $1.04, with an estimated average price of $0.81. The stock is now traded at around $0.89. The impact to a portfolio due to this purchase was 0.13%. The holding were 372,557 shares as of .
Added: Immunogen Inc (IMGN)Birchview Capital, LP added to a holding in Immunogen Inc by 309.09%. The purchase prices were between $2.41 and $5.91, with an estimated average price of $4.37. The stock is now traded at around $2.88. The impact to a portfolio due to this purchase was 0.11%. The holding were 90,000 shares as of .
Sold Out: Harrow Health Inc (HROW)Birchview Capital, LP sold out a holding in Harrow Health Inc. The sale prices were between $4.75 and $7.1, with an estimated average price of $6.04.
Sold Out: AMAG Pharmaceuticals Inc (AMAG)Birchview Capital, LP sold out a holding in AMAG Pharmaceuticals Inc. The sale prices were between $11.29 and $17.05, with an estimated average price of $14.96.
Here is the complete portfolio of Birchview Capital, LP. Also check out:
1. Birchview Capital, LP's Undervalued Stocks
2. Birchview Capital, LP's Top Growth Companies, and
3. Birchview Capital, LP's High Yield stocks
4. Stocks that Birchview Capital, LP keeps buying